Characterizing Cerebral Amyloid Angiopathy
Official title: Phenotypic and Molecular Characterisation of Early-onset Cerebral Amyloid Angiopathy
Run by University Hospital, Rouen · NCT06864000 · Data updated 2026-11-12
This study is trying to find out if certain genetic changes are linked to cerebral amyloid angiopathy, a condition that causes brain bleeding and memory problems, by looking at blood samples from patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Rouen Academic / other |
| Locations | 1 site (Rouen) |
| Status | Recruiting |
| Started | March 31, 2023 |
| Main results expected | July 30, 2027 |
| Study ends | December 30, 2027 |
| Registry record updated | March 7, 2025 |
| Trial ID | NCT06864000 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with cerebral amyloid angiopathy under the age of 66 who have consented to genetic research.
✕Probably not a fit
Patients over the age of 66 or those with identified APP mutations or duplications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on cerebral amyloid angiopathy (CAA), a severe condition characterized by amyloid deposits in cerebral vessels, leading to recurrent cerebral hematomas and cognitive decline. It aims to investigate the genetic components associated with CAA by analyzing blood samples for mutations or duplications of the APP gene and other susceptibility factors. The study will compare genetic variant carriers between cases and controls using statistical methods to better understand the disease's progression and diagnosis. The research is conducted at the Rouen University Hospital, leveraging national patient recruitment.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of genetic factors in cerebral amyloid angiopathy, potentially leading to improved diagnostic and prognostic tools.
How similar studies have gone: While studies on genetic factors in related conditions exist, this specific focus on cerebral amyloid angiopathy and its genetic characterization is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a diagnosis of cerebral amyloid angiopathy (CAA) whose genetic samples are initially sent to the Rouen or Paris-Lariboisière genetics laboratories for molecular diagnosis of a genetic cause, thanks to national recruitment and for whom the patients consent to continuing genetic analyses for research purposes without feedback. * Diagnosis of cerebral amyloid angiopathy (CAA) certain or probable according to the modified Boston diagnostic criteria (1) (except age) * Age of onset of symptoms \<66 years * Absence of APP mutation/duplication (analysis must already have been carried out in the laboratory on receipt of the sample as part of routine care) * Signed consent for research * Patient covered by a social security scheme Exclusion Criteria: * Age at first neurological symptom \> 66 years * Minor patients * Other differential diagnosis that better explains the clinical situation * Identification of mutations or duplication of the APP gene * AAC possible but not probable according to the revised Boston criteria * Patient deprived of liberty by judicial or administrative decision
Where it's running
-
University Hospital Rouen
Rouen, France Recruiting
Study contacts
- Principal investigator: Lou LG GRANGEON, Doctor — University Rouen Hospital
- Study coordinator: David DM MALLET, Director
- Email: Secretariat.DRC@chu-rouen.fr
- Phone: +33 2 32 88 82 65
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if preoperative anxiety affects recovery after major digestive cancer surgery
This study tests whether anxiety before surgery is linked to more complications after major digestive cancer operations in French-speaking adults.
-
Using EEG to monitor sleep quality in ICU patients with respiratory failure
We will test whether continuous EEG monitoring can better track sleep quality than nurse observations in conscious adults hospitalized in the ICU for acute respiratory failure.
-
Gynecological and sexual aftereffects following rectal cancer treatment
This work will test whether gynecological anatomical changes after rectal cancer treatment are linked to ongoing sexual problems in women aged 18–60 who are in remission.
-
Long-read genetic analysis for Spinal Muscular Atrophy (LOREASI)
This project tries a long-read DNA technique on adults with known SMN1 copy-number patterns to find hidden '2+0' carrier genotypes that standard tests miss.
-
Carotid artery wall viscosity and memory problems in older adults
This project will test whether the viscous behavior of the carotid artery wall is linked to memory problems in people over 70 with memory complaints, Alzheimer's disease, or vascular dementia.
-
How gut bacteria from women with eating disorders affect digestion and behavior
This project will test whether gut bacteria taken from women with anorexia, bulimia, or binge-eating cause changes in digestion and eating-related behavior when transplanted into mice, compared with bacteria from healthy women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.